MF59- and Al(OH)3-adjuvanted Staphylococcus aureus (4C-Staph) vaccines induce sustained protective humoral and cellular immune responses, with a critical role for effector CD4 T cells at low antibody titers

Frontiers in Immunology

Volumn 6, Issue SEP, 2015, Pages

  Monaci, Elisabetta ^a   Mancini, Francesca ^a,b   Lofano, Giuseppe ^a,c,e   Bacconi, Marta ^a,d   Tavarini, Simona ^a   Sammicheli, Chiara ^a   Arcidiacono, Letizia ^a   Giraldi, Monica ^a   Galletti, Bruno ^a   Paccani, Silvia Rossi ^a   Torre, Antonina ^a   Fontana, Maria Rita ^a   Grandi, Guido ^a,f   de Gregorio, Ennio ^a   Bensi, Giuliano ^a   Chiarot, Emiliano ^a   Nuti, Sandra ^a   Bagnoli, Fabio ^a   Soldaini, Elisabetta ^a   Bertholet, Sylvie ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f UNIVERSITY OF TRENTO   (Italy)

Author keywords

Adjuvant; Antibodies; Bacterial infection; Mice; Staphylococcus aureus; T cells; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HLA ANTIBODY; IMMUNOGLOBULIN G; MIFAMURTIDE; NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE DEPLETION; NONHUMAN; PERITONITIS; STAPHYLOCOCCUS AUREUS;

EID: 84949558711     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00439     Document Type: Article

References (40)

1. Yeaman MR, Filler SG, Chaili S, Barr K, Wang H, Kupferwasser D, et al. Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proc Natl Acad Sci U S A (2014) 111(51):E5555-63. doi:10.1073/pnas.1415610111
2. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: "Staphylococcus aureus vaccines: problems and prospects". Vaccine (2013) 31(25):2723-30. doi:10.1016/j.vaccine.2013.04.002
3. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 309(13):1368-78. doi:10.1001/jama.2013.3010
4. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med (2014) 6(6):708-20. doi:10.1002/emmm.201403876
5. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 2:16. doi:10.3389/fcimb.2012.00016
6. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med (1988) 85(2):172-6. doi:10.1016/S0002-9343(88)80337-1
7. Trakultivakorn M, Ochs HD. X-linked agammaglobulinemia in northern Thailand. Asian Pac J Allergy Immunol (2006) 24(1):57-63.
8. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 5(12):e1000703. doi:10.1371/journal.ppat.1000703
9. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother (2012) 8(3):336-46. doi:10.4161/hv.18946
10. Bagnoli F, Fontana MR, Soldaini E, Mishra RPN, Fiaschi L, Cartocci E, et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A (2015) 112(12):3680-5. doi:10.1073/pnas.1424924112
11. Sebulsky MT, Heinrichs DE. Identification and characterization of fhuD1 and fhuD2, two genes involved in iron-hydroxamate uptake in Staphylococcus aureus. J Bacteriol (2001) 183(17):4994-5000. doi:10.1128/JB.183.17.4994-5000.2001
12. Mishra RPN, Mariotti P, Fiaschi L, Nosari S, Maccari S, Liberatori S, et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis (2012) 206(7):1041-9. doi:10.1093/infdis/jis463
13. Mariotti P, Malito E, Biancucci M, Lo Surdo P, Mishra RP, Nardi-Dei V, et al. Structural and functional characterization of the Staphylococcus aureus virulence factor and vaccine candidate FhuD2. Biochem J (2013) 449(3):683-93. doi:10.1042/BJ20121426
14. Schluepen C, Malito E, Marongiu A, Schirle M, McWhinnie E, Lo Surdo P, et al. Mining the bacterial unknown proteome: identification and characterization of a novel family of highly conserved protective antigens in Staphylococcus aureus. Biochem J (2013) 455(3):273-84. doi:10.1042/BJ20130540
15. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis (2010) 202(7):1050-8. doi:10.1086/656043
16. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med (2008) 205(2):287-94. doi:10.1084/jem.20072208
17. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun (2009) 77(7):2712-8. doi:10.1128/iai.00115-09
18. Menzies BE, Kernodle DS. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun (1996) 64(5):1839-41.
19. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, et al. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One (2013) 8(10):e75103. doi:10.1371/journal.pone.0075103
20. Burts ML, Williams WA, DeBord K, Missiakas DM. EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of Staphylococcus aureus infections. Proc Natl Acad Sci U S A (2005) 102(4):1169-74. doi:10.1073/pnas.0405620102
21. Korea CG, Balsamo G, Pezzicoli A, Merakou C, Tavarini S, Bagnoli F, et al. Staphylococcal Esx proteins modulate apoptosis and release of intracellular Staphylococcus aureus during infection in epithelial cells. Infect Immun (2014) 82(10):4144-53. doi:10.1128/IAI.01576-14
22. Zhang BZ, Hua YH, Yu B, Lau CC, Cai JP, Zheng SY, et al. Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model. Infect Immun (2015) 83(1):339-45. doi:10.1128/IAI.02498-14
23. Menzies BE, Kernodle DS. Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun (1994) 62(5):1843-7.
24. Torre A, Bacconi M, Sammicheli C, Galletti B, Laera D, Fontana MR, et al. 4C-Staph vaccine enhances Fcgamma receptors expression in neutrophils and monocytes and mitigates Staphylococcus aureus infection in neutropenic mice. Infect Immun (2015) 83(8):3157-63. doi:10.1128/IAI.00258-15
25. Spadea A, Unim B, Colamesta V, Meneghini A, D'Amici AM, Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine (2014) 32(41):5290-4. doi:10.1016/j.vaccine.2014.07.077
26. Yoshida K, Ichiman Y. Successive extraction of specific protective immunoglobulins from pooled human sera. J Clin Microbiol (1984) 20(3):461-4.
27. Ventura A, Ciana G, Florean P, Longo F, Longo G. The effect of bacterial infection in the worsening of atopic dermatitis: correlations with humoral immunologic patterns. Ann Allergy (1989) 63(2):121-6.
28. Lee AH, Levinson AI, Schumacher HR Jr. Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum (1993) 22(4):252-64. doi:10.1016/0049-0172(93)80073-O
29. Castanet J, Lacour JP, Perrin C, Brun P, Ortonne JP. Juvenile pityriasis-rubra-pilaris associated with hypogammaglobulinemia and foruncolosis. Br J Dermatol (1994) 131(5):717-9. doi:10.1111/j.1365-2133.1994.tb04991.x
30. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med (2002) 346(7):491-6. doi:10.1056/NEJMoa011297
31. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis (2012) 54(4):560-7. doi:10.1093/cid/cir828
32. Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother (2015) 11(3):632-41. doi:10.4161/hv.34414
33. Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med (2012) 13(6):319-32. doi:10.1111/j.1468-1293.2011.00978.x
34. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 452(7188):773-6. doi:10.1038/nature06764
35. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest (2010) 120(5):1762-73. doi:10.1172/JCI40891
36. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity (2009) 30(1):108-19. doi:10.1016/j.immuni.2008.11.009
37. Montgomery CP, Daniels M, Zhao F, Alegre ML, Chong AS, Daum RS. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun (2014) 82(5):2125-34. doi:10.1128/IAI.01491-14
38. von Köckritz-Blickwede M, Rohde M, Oehmcke S, Miller LS, Cheung AL, Herwald H, et al. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am J Pathol (2008) 173(6):1657-68. doi:10.2353/ajpath.2008.080337
39. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 332(6025):65-8. doi:10.1126/science.1200439
40. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol (2011) 186(3):1666-74. doi:10.4049/jimmunol.1002194